Estimates are that roughly 1 percent of people in Western countries may have bile acid diarrhea, including patients with Crohn's disease, ileal resection, diarrhea-predominant irritable bowel syndrome (IBS-D), and chronic functional diarrhea. Current management for bile acid diarrhea has demonstrated limited efficacy, with some therapies producing significant side effects. A recent study published in The FASEB Journal explored the efficacy of CFTR (cystic fibrosis transmembrane conductance regulator) inhibition to reduce excessive secretion in the colon due to bile acids.
* This article was originally published here
